Advanced Biomed (ADVB) Cash & Equivalents (2023 - 2026)

Advanced Biomed has disclosed Cash & Equivalents across 4 years of filings, most recently posting $2.6 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $2.6 million, down 18.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.6 million (down 18.06% YoY), and the FY2025 annual result was $2.9 million, up 11.35% from the prior year.
• Cash & Equivalents came in at $2.6 million for Q1 2026 at Advanced Biomed, roughly flat from $2.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $3.2 million in Q1 2025 to a low of $2.6 million in Q1 2026.
• The 4-year median for Cash & Equivalents is $2.7 million (2024), against an average of $2.7 million.
• Across the five-year window, Cash & Equivalents grew 19.25% in 2025 and retreated 18.06% in 2026, its largest moves.
• Advanced Biomed's Cash & Equivalents stood at $2.8 million in 2023, then slipped by 4.64% to $2.6 million in 2024, then dropped by 1.62% to $2.6 million in 2025, then slipped by 0.08% to $2.6 million in 2026.
• The last three Cash & Equivalents figures came in at $2.6 million (Q1 2026), $2.6 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.